This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 77 entries.
‘Botanix Pharmaceuticals (ASX:BOT) shares have soared after a small clinical trial backed the feasibility of putting synthetic cannabis up the nose of surgical patients to prevent infections. While cannabis is of course mostly known for its psychoactive properties, a number of companies trying to unlock its therapeutic benefit and Botanix’s research has shown that cannabidiol (CBD) is […]
Philadelphia PA and Sydney Australia, 3 February 2021: Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals Limited has today published positive data from a world first human clinical study, examining the safety, tolerability and efficacy of its BTX 1801 antimicrobial product for the eradication of Staphylococcus Aureus (Staph). Staph, also called golden staph, is a common […]
Groundbreaking new research has found synthetic cannabidiol can kill bacteria associated with gonorrhoea, meningitis and legionnaires disease. The research, published in a peer-reviewed journal article in Communications Biology on Wednesday, explores antimicrobial activity of CBD and the potential to advance CBD analogs as a “much-needed new class of antibiotics”. It found the psychoactive component of […]
Queensland researchers are studying a component of medicinal cannabis for its potential as a new antibiotic, capable of killing superbugs. The big hope for scientists at the University of Queensland’s Institute for Molecular Bioscience is that synthetic cannabidiol, or CBD, the main non-psychoactive component of cannabis, could be developed into the first new class of […]
An important research project testing the targeted capabilities of our antimicrobial platform, conducted in collaboration with The University of Queensland, has been published in Communications Biology – a leading peer-reviewed journal by Nature Research. The research article titled “The antimicrobial potential of cannabidiol” reveals the unique mechanism through which synthetic cannabidiol can kill the bacteria […]
Oxford University is opening a new research institute dedicated to tackling resistance to antibiotics. The university says this is one of the the biggest rising threats to global health, already causing 1.5 million deaths per year worldwide. The institute will be funded by £100m donated by the Ineos chemical company. Click through to read the […]
Synthetic cannabidiol, better known as CBD, has been shown for the first time to kill the bacteria responsible for gonorrhoea, meningitis and legionnaires disease. The research collaboration between The University of Queensland and Botanix Pharmaceuticals Limited could lead to the first new class of antibiotics for resistant bacteria in 60 years. The UQ Institute for […]
Superbugs were this week labelled as “the next great health crisis of our time” and there are a few ASX stocks seeking to address it. Superbugs are bacteria, viruses, fungi and parasites immune to conventional antibiotics and pharmaceuticals. Yesterday, on the eve of World Antimicrobial Resistance Awareness Week, Monash University has warned superbugs could kill […]
“Is this just a projection…?” The narrator of this video asks, as she examines the possibility of a world devoid of effective antibiotics, a most precious resource. Due to “use, misuse, overuse” of antibiotics, a dire future is forecast. It is thought provoking, unnerving – but also deeply motivating to be part of global action […]
AusBiotech’s BiotechDispatch featured our BTX 1801 antimicrobial program update today. Read the full article here.
AUSTRALIA
Level 1, 50 Angove Street, North Perth WA 6006
USA
3602 Horizon Drive, Suite 160, King of Prussia, PA 19406
Be notified of important news from Botanix.
AU +61 8 6555 2945
US + 1 445 300 3403
info@botanixpharma.com